For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
REGULATORY
Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
Five new “probable” cases of children with acute hepatitis of unknown etiology were reported in Japan, bringing the total number of such detections to 36, the Japanese health ministry said on June 3. According to the WHO’s tentative definition, a…
To read the full story
Related Article
- Japan Detects 14 More Probable Cases of Pediatric Hepatitis
September 20, 2022
- 8 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 26, 2022
- Japan Detects 4 More Probable Cases of Pediatric Hepatitis
July 11, 2022
- 5 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 4, 2022
- Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
June 27, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- 7 New Probable Cases of Pediatric Hepatitis Reported in Japan
May 31, 2022
- 12 New Probable Cases of Mysterious Pediatric Hepatitis Detected in Japan
May 23, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
- Probable Cases of Mysterious Pediatric Hepatitis Now Increased to 7 in Japan
May 9, 2022
REGULATORY
- Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures
December 2, 2024
- Pharma Industry Makes Plea to Komeito to Scrap Off-Year Revisions
December 2, 2024
- Japan Partially Eases Rule for Use of Abortion Pill Mefeego
December 2, 2024
- MOF Panel Wants Prioritized Budgeting for Drug Costs: Subcommittee Acting Chair
December 2, 2024
- MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…